Antigen expression in leukaemia v1.0
Research type
Research Study
Full title
Antigen expression in leukaemia: Targets for therapy and biomarkers of disease status
IRAS ID
311338
Contact name
Barbara Guinn
Contact email
Sponsor organisation
University of Hull
Duration of Study in the UK
10 years, 0 months, 0 days
Research summary
The development of immunotherapies, small molecule and personalised treatments for use in conjunction with conventional therapy offers new ways to remove residual disease and reduce the risk of relapse in leukaemia patients. Our group have been identifying novel genes by virtue of the (B cell) immune responses generated specifically in leukaeia patients and increasingly in silico studies. These gene products are leukaemia associated antigens (LAAs). In addition the identification of LAAs, whose expression is subverted in haematological malignancy development, will help our understanding of the genetic errors which lead to leukaemia development, identify markers of disease progression and as well as help in the preparation of treatments that can effectively remove residual diseased cells in first remission hopefully delaying, if not preventing, relapse.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
22/SC/0475
Date of REC Opinion
2 Mar 2023
REC opinion
Further Information Favourable Opinion